MK-677 (Ibutamoren) + Epitalon Stack: Safety and Monitoring Guide

Print or save as PDFOpens the printable lab tracker and your print dialog. No sign-up.

What each compound actually is

MK-677 (ibutamoren mesylate) is an oral, non-peptide small molecule that stimulates growth hormone release by acting on the ghrelin receptor, raising IGF-1 [8]. Merck first synthesized it in 1995 and discontinued development in 1999; it has no USP or National Formulary monograph and is not part of any FDA-approved drug [8]. It is not a SARM, although it is often sold alongside them [8]. Under the name LUM-201 it is being studied in children with growth hormone deficiency; a randomized placebo-controlled trial of 68 prepubertal children gave oral LUM-201 for six months, with increased appetite the most common drug-related event [9][8].

Epitalon is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, molecular weight about 390 g/mol as the free base [3]. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland; FDA treats epitalon and epithalamin as different substances, so epithalamin studies are not epitalon studies [3]. The most-cited laboratory result is that adding epitalon to telomerase-negative human fetal fibroblast cultures induced the telomerase catalytic subunit, telomerase activity and telomere elongation [10]. That is a cell-culture finding, not a human outcome.

What MK-677 changed in trials

Blood glucose and HbA1c. In 65 healthy adults aged 60 to 81 given 25 mg daily, fasting glucose rose by about 5 mg/dL over 12 months (P=0.015) and insulin sensitivity fell [4][8]. In 32 healthy adults aged 64 to 81 randomized to placebo or 2, 10 or 25 mg daily, fasting glucose at 25 mg went from 5.4 to 6.8 mmol/L after four weeks (P<0.01 vs. baseline) [11]. Among 563 people with Alzheimer's disease treated for 12 months, glucose increases occurred in 15.4% on MK-677 versus 4.6% on placebo, and HbA1c increases in 11.1% versus 1.4% [7][8]. In 161 hip-fracture patients over six months, glucose rose 8.0 mg/dL while falling 1.6 mg/dL on placebo, and HbA1c rose 0.7% versus 0.3% [12][8]. In 24 obese men, an oral glucose tolerance test showed impaired glucose handling at 2 and 8 weeks [6][8].

IGF-1. Rises were large in every trial: 72.9% at 12 months in Alzheimer's disease [7], 84% versus 17% after hip fracture [12][8], 39% to 45% in postmenopausal women with osteoporosis [5], 51.4 ng/mL above placebo in the Adunsky hip-fracture trial [2], and about 40% in obese men [6]. FDA's concern is that raising GH and IGF-1 carries the risks listed on approved growth hormone labels — increased risk of neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism and pancreatitis — and that higher IGF-1 appears linked to cancer risk across ages [8].

Fluid, blood pressure and heart failure. The Adunsky trial (123 patients aged 60 or older, 25 mg daily for 24 weeks) was terminated early for a safety signal of congestive heart failure: per FDA's summary, 4 patients (6.5%) on MK-677 versus 1 (1.7%) on placebo. Systolic blood pressure rose 11.9 to 16.4 mmHg versus 2.3 to minus 2.3 mmHg on placebo, serious adverse events occurred in 24% versus 13%, and the authors concluded MK-0677 has an unfavorable safety profile in this population [2][8]. In the Bach trial of 161 hip-fracture patients, edema or fluid overload was recorded in 16 versus 10 patients, thrombosis in 4 versus 0, serious adverse events in 24% versus 18%, and 12% versus 2.6% stopped treatment for adverse events [12][8]. Increased appetite and transient mild leg edema were the most frequent side effects in the Nass trial [4].

Liver, appetite and hormones. Asymptomatic transaminase rises of 1.5 to 4 times normal, reversible, occurred in some trials, including 18 children given 0.2 or 0.8 mg/kg/day for 7 to 8 days [13][8]. Prolactin rose 23% but stayed within the normal range in one four-week study [11]; cortisol rose in the Nass trial [4][8] but not in obese men at 2 and 8 weeks [6]. In the Nass trial body weight rose 2.7 kg versus 0.8 kg and fat-free mass rose 1.1 kg versus a 0.5 kg fall, with no improvement in strength or function [4].

What the epitalon record shows

FDA found only three human studies of epitalon — two sublingual studies in night-shift workers and one injection beside the eye in retinitis pigmentosa — and no clinical study that assessed its safety [3]. One small study gave no safety data, and the 'no side effects' claim traces to a Russian-language abstract that gave no dose, route or number of people [3]. FDA also found no pharmacokinetic data and raised an immunogenicity concern for subcutaneous injection, noting that injectable peptides may carry aggregation and impurity risks [3][1]. An FDA adverse-event database search through December 8, 2025 and a food and supplement complaint search through December 5, 2025 retrieved no epitalon reports [3].

FDA warned that because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic; the mouse studies of cancer and chromosome damage were too limited — one fixed dose, female mice only, short exposure — to show safety [3].

The human data are thin. In a placebo-controlled study of 75 healthy women aged 40 to 50, mostly night-shift workers, 40 with low melatonin output were split into two groups of 20 and given a sublingual spray delivering about 0.5 mg/day or placebo for 20 days; urinary 6-sulfatoxymelatonin rose about 1.7-fold on epitalon and did not change on placebo, and 83% versus 25% were described as improved in mood and physical condition, but no sleep outcomes were measured [3]. A 2002 controlled study in retinitis pigmentosa injected epitalon beside the eye and reported a positive clinical effect in 90% of cases [14]; it is old, has not been replicated, and is not a modern randomized trial [14][15]. A 2026 narrative review concluded that epitalon is biologically active but clinically unproven, with no adequately powered randomized trial and inadequate pharmacokinetic, dose-ranging and long-term safety data [15].

MK-677 with alendronate

In a 12-month trial of 292 postmenopausal women with osteoporosis, MK-677 25 mg plus alendronate 10 mg partly offset alendronate's drop in bone-turnover markers (osteocalcin fell 40% versus 54% with alendronate alone) and raised femoral neck bone density 4.2% versus 2.5% with alendronate alone, with no extra gain at the spine, total hip or total body; 8.6% of women across all four arms stopped for adverse events judged treatment-related [5][8]. FDA's review reports no formal drug-interaction studies of MK-677 [8].

Regulatory status of each

MK-677 is in FDA's category of bulk substances that raise significant safety risks when compounded, added December 29, 2022 for outsourcing facilities and September 29, 2023 for state-licensed pharmacies and physicians, with the stated reason being a potential for congestive heart failure in certain patients [1][16][17][2]. FDA's Pharmacy Compounding Advisory Committee voted 1 yes, 13 no against adding ibutamoren to the pharmacy bulks list on October 29, 2024, citing fluid retention, congestive heart failure and hyperglycemia [18][8]. FDA's December 12, 2025 warning letter states that ibutamoren is excluded from the dietary supplement definition and that products marketed with drug claims are unapproved new drugs [19]; in September 2025 FDA warned that a children's growth product contained undeclared ibutamoren, listing increased appetite, water retention, fatigue, muscle pain, altered glucose metabolism and a potential for congestive heart failure as risks [20]. WADA names ibutamoren in class S2.2.4, prohibited at all times [21][22].

Epitalon is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [3]. FDA's page on bulk substances that may raise significant safety risks lists epitalon in the table of substances whose nominators withdrew them, and FDA's stated concern is that it has not identified safety-related information for the proposed route of administration; removal from the earlier risk category was not a finding that it is safe [1]. It appears in none of the three categories on FDA's lists for state-licensed pharmacies and physicians or for outsourcing facilities [16][17][23]. FDA staff proposed in July 2026 that neither epitalon free base nor epitalon acetate be added to the pharmacy bulks list, evaluating only insomnia, where it found no evidence of effectiveness and no clinical safety data [3]. The advisory committee voted in favor of adding it on July 24, 2026, against staff's recommendation, but that vote is advice only and not binding, and epitalon is not on the list [24][25]. HHS's draft enforcement-discretion policy, filed October 28, 2026, names epitalon acetate for subcutaneous or intramuscular use in intermittent courses and says HHS does not intend to take enforcement action against certain pharmacies and physicians if its conditions are met; the notice states it is not binding and creates no rights, and it is not an approval or a listing [25][26]. MK-677 is not among the six peptides that policy names [25][26]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [27].

What the trials can and cannot support for monitoring

The trials report measurements, not a validated monitoring schedule for MK-677 with epitalon. What exists is the set of measurements the trials themselves made: fasting glucose and HbA1c, IGF-1, blood pressure, body weight and fluid status, liver enzymes, and in some protocols prolactin and cortisol [4][11][2][12][13]. The Nass trial assessed endpoints at baseline and every six months [4]; Chapman sampled at baseline and day 14 of each study period [11]; Adunsky ran 24 weeks [2].

Some trial populations excluded higher-risk people: the Bach trial excluded patients with diabetes mellitus, cancer, uncontrolled hypertension and congestive heart failure [12]. FDA also notes there are no long-term safety data in the older adults the drug is marketed to [8].

What is not known

The MK-677 trials cited here ran from 4 weeks to 2 years [11][4][2][12][7]. For epitalon, pharmacokinetics, dose-ranging and long-term safety remain inadequate, and oncologic and product-quality questions were left unresolved after the 2026 advisory review [15].